VX-950 and Peginterferon for Hepatitis C

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

• Phase: Phase 1

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated

Criteria

Inclusion Criteria:

• infected with Hepatitis C virus

Exclusion Criteria:

• contraindications to peginterferon therapy